Qiming Venture Partners’ Post

Great progress at Nimbus Therapeutics! We're advancing our novel WRN Inhibitor, NTX-452, with plans to enter the clinic in the first half of 2025. I’m here at the 36th EORTC-NCI-AACR Symposium in beautiful Barcelona where our team is presenting our preclinical poster on NTX-452 (https://lnkd.in/drbaju7x) For cancers with microsatellite instability (MSI)—often found in the GI tract and endometrium—faulty DNA structures lead to cell death. However, these cancers rely on WRN helicase to survive by resolving these DNA issues. WRN inhibition can thus significantly impact a broad number of patients that have high MSI. At Nimbus, we've developed both covalent and non-covalent WRN inhibitors. Our lead candidate, a non-covalent compound, NTX-452, stands out with its best-in-class potential and excellent drug-like properties and pharmacology package. Look forward bringing this breakthrough to patients and make a real impact 🙏 #ENASymp24 #NimbusTherapeutics #CancerResearch #WRNInhibitor #Biotech #Drugdiscovery

We'll be hosting a webinar related to the discovery and development of Antibody Drug Conjugates on Friday, Septmeber 13th from 10-10:30am PST. Don't be scared away by the date! REGISTER NOW: https://lnkd.in/gs2ti4k4 Topics covered: -Selection and optimization of immunoassays from relevant preclinical tumor models using ADCs -Pharmacokinetics, Pharmacodynamics, and Immunogenicity considerations using an open MSD platform for any ADC -Potential safety and efficacy biomarkers to port to the open MSD platform #antibodydrugconjugates #immunooncology #immunoassays #ADCs #biomarkers #bioanalysis

"Amazing news from the field of small molecule Degrader #DrugDevelopment!" Congratulations to Michael Kort, Marcia Paddock, Christopher Nasveschuk and colleagues from AbbVie, Calico Life Sciences, C4 Therapeutics, Inc. and NanoImaging Services who together successfully developed potent protein tyrosine phosphatase non-receptor type 2/1 (PTPN2/N1) dual heterobifunctional degraders (Cmpd-1 and Cmpd-2) published in Nature Portfolio Communications Chemistry: https://lnkd.in/e-JNY7E5 "#TargetedProteinDegradation (TPD) has emerged as a promising approach to drug challenging targets including phosphatases. Phosphatases have historically been very difficult to drug because they lack a classical ATP binding pocket and their active site is highly polar, making it an attractive #DrugTarget for degrader design in #ImmunoOncology! PTPN2 and the closely related PTPN1 were found to be appealing targets in an unbiased screen looking for tumor proteins that could be targeted to increase #Immunotherapy efficacy. ABBV-CLS-484, a #SmallMolecule lead compound, is currently in Phase 1 clinical trials for the treatment of locally advanced or #Metastatic tumors. Degraders are an increasingly important modality in drug development because they allow for the targeting of proteins which may be otherwise difficult to drug (e.g., PTPNs) by recruiting them to E3 ubiquitin ligases (e.g. CRL4-CRBN)!" The team employed a combination of structural approaches to provide mechanistic insights into the cooperative complex formation and #MechanismOfAction" introduced by degraders. A high resolution #CryoEM structure of CRBN/Cmpd-1/PTPN2 revealed that the #Degrader induces proximity between CRBN and PTPN2, albeit the large conformational heterogeneity of this ternary complex! These insights demonstrate the development of PTPN2/N1 heterobifunctional degraders with potential applications in #Cancer immunotherapy. Furthermore, the developed structural workflow could help to understand the dynamic nature of degrader-induced cooperative ternary complexes! #Oncology #TPD #DrugDesign

Gursev Anmole, Scientist, In Vitro Pharmacology, Multispecific Antibody Therapeutics, and Prajwal Raghunatha, Associate Scientist, Protein Engineering, Multispecific Antibody Therapeutics will deliver a poster presentation at #PEGSummit this week exploring our TriTCE Co-Stim technology platform, a next generation trispecific T cell engager platform with integrated CD28 costimulation engineered to improve T cell function and antitumor responses in difficult-to-treat cancers. Learn more about PEGS Boston taking place May 13-17: https://lnkd.in/g-q2viTs

Artiva Biotherapeutics is looking to raise up to $135 million from an Initial Public Offering (IPO) to fund clinical trials for its leading allogeneic natural killer (NK) cell therapy. The San Diego-based company revealed these plans in a recent Securities and Exchange Commission filing, with expectations of selling 8.7 million shares priced between $14 and $16 each 💰 💵 The major focus for the proceeds will be on advancing the clinical development of AlloNK, a non-genetically modified, cryopreserved NK cell therapy. Currently, AlloNK is being tested in a phase 1 trial for lupus nephritis alongside Roche's Rituxan or Gazyva. It's also part of another study that spans multiple autoimmune indications. By the first half of 2025, we should see some promising data readouts 📉 #Biotechnology #ArtivaBiotherapeutics #ClinicalTrials #NKCellTherapy #IPO #LifeScience #ElixirAssociates #StaffingPartner

Stay up to date on all things #IO and register for tomorrow's #SITC Targets for Cancer IO: A Deep Dive into Clinical Consideration for CD3-Bispecifics and Costimulatory T cell Engagers in Solid #Tumors Webinar! Moderators: Jeremy Myers, PhD - EvolveImmune Therapeutics & Dimitris Skokos, PhD - Regeneron Pharmaceuticals, Inc. Faculty: John Desarjais, PhD - Xencor, Christian Klein, PhD - Roche Innovation Center Zurich & Elizabeth Pham, PhD - Amgen Inc. This webinar will address current studies to develop more effective, safer CD3-targeting bispecific T #cell engagers that maintain clinical efficacy within the immunosuppressive #TME while minimizing cytokine release and other on-target, off-tumor toxicities. Save your spot for tomorrow's webinar: go.sitcancer.org/3YtTUNh

🚀 Unlock the Future of Therapeutics with Nanobodies! Join us on Oct 23 at 11:00 AM EST for an insightful webinar hosted by Biocytogen: "Exploring Fully Human Nanobodies for Innovative Disease Treatments". Speaker: Dr. Yongfei Yang, Director of the Antibody Research Institute at Biocytogen 📢 What you'll learn: - Exceptional properties of nanobodies in developing various drug modalities. - Case studies on GPRC5D, 4-1BB, and TFR1 antibodies, showcasing sequence diversity, optimal affinity, hydrophilicity, and pharmacokinetics. - How Biocytogen’s RenNano and Beacon platforms accelerate nanobody development. - Applications of fully human HCAbs from RenNano mice in bispecific/ multispecific antibodies, XDC, and cell therapies. Register here: https://lnkd.in/et4M-FXh #Biocytogen #DrugDevelopment #Biotechnology #AntibodyResearch #HealthcareInnovation #AntibodyTherapeutics #MedicalResearch

Are you heading to ISCT in Vancouver? Can you believe it? It's only a few short weeks away! 📰 Our agenda is packed with opportunities to explore and move forward with your advanced therapeutics — from exciting speakers to thought-provoking sessions, and educational posters you won't want to miss: 👉 End-to-end manufacturing of autologous CAR T cell therapies with a new cell therapy manufacturing platform 👉 Regulatory T cell expansion in the Xuri cell expansion system W25 👉 Closed, semi-automated harvest of iPSC scale-up workflow using the Sepax C-Pro with CultureWash protocol 👉 Optimization of multiplex CRISPR-Cas9 editing of human primary T cells using lipid nanoparticles (LNPs) and subsequent off-target evaluation 👉 Strategies for producing clinical and commercial RNA-LNP drug products And there's more...follow this link to discover all the ways you can connect with us at ISCT: https://lnkd.in/gJpJc2PS

Last day of #BIOEuropeSpring by EBD Group in Barcelona, but not last chance to engage with peers in drug discovery and pharmaceuticals. At Indivumed Therapeutics we strive to bring novel therapies to treat #cancer patients. Collaborations and partnerships are crucial to advance together to bring #targetdiscovery programs to the clinical stage. Stay tuned! #clinicalresearch #beyondgenomics #proteomics #phosphoproteomics #data #multiomics #mathematics #bioinformatics

I’m excited to share that our manuscript has been published online in Neurotherapeutics and is currently 'in press'!  At NovaGo Therapeutics, our goal is to restore mobility and improve quality of life for spinal cord injury patients. To achieve this, we have developed a monoclonal antibody that targets Nogo-A, a negative regulator of nerve growth located in the central nervous system. In this preclinical study, we evaluated the safety, pharmacokinetics, and pharmacodynamics of our anti-Nogo-A antibody when administered intrathecally into the central nervous system of non-human primates.   I’m honored to have contributed to this project as a first author and am looking forward to the initiation of Phase I clinical trials by the end of this year. You can read the full paper here: https://lnkd.in/g5_cBzG3